[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthritis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,49,74,98,141,173,196,220,244,269,294,321,350,379,406,453,475,508,530,554,603,640,662,685,717],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100324933","natural-history-genetics-and-pathophysiology-of-systemic-juvenile-idiopathic-arthritis-adult-onset-stills-disease-and-related-conditions-100324933",false,"NCT03510442","Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions","Investigation of the Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease and Related Inflammatory Conditions","* INCLUSION CRITERIA:\n\nSubjects with known or suspected sJIA, AOSD or a similar inflammatory phenotype will provide informed consent and then be evaluated either in the outpatient or inpatient unit of the NIH Clinical Center. To be eligible for follow-up visits patients must meet the Inclusion Criteria, but not the Exclusion Criteria. Subjects determined to not have known or suspected sJIA or AOSD, or a related\n\ninflammatory phenotype, will not be followed.\n\nPatients with signs and symptoms of sJIA will be classified as outlined in #1, #2 and #3 below:\n\n1. Patients less than 16 years of age will be considered to have sJIA if they meet the ILAR criteria for sJIA.\n2. Patients 16 years of age and older will be considered to have sJIA if they have previously met ILAR criteria for sJIA.\n3. Family members of individuals included under items 1 and 2.\n4. Controls for clinical, cellular, molecular, and biochemical assays, and genetic evaluation will be enrolled. Individuals who undergo phlebotomy specifically to provide a control specimen will include both pediatric and adult patients and will not be pregnant.\n\nPatients with signs and symptoms of AOSD will be classified as outlined in #1, #2 and #3 below:\n\n1. Patients 16 years of age and older will be considered to have AOSD if they meet the Yamaguchi criteria for AOSD (including a negative ANA and RF).\n2. Patients may be considered to have a diagnosis of AOSD if they met criteria for diagnosis in the past but do not still have present evidence of disease.\n3. Family members of individuals included under items 1 and 2.\n4. Controls for clinical, cellular, molecular, and biochemical assays, and genetic evaluation will be enrolled. Individuals who undergo phlebotomy specifically to provide a control specimen will include both pediatric and adult patients and will not be pregnant.\n\nPatients with suspected sJIA, AOSD or a related inflammatory condition, as indicated by the presence of episodic fever and\u002For arthritis, may also be included.\n\nEXCLUSION CRITERIA:\n\n1. In adults, inability to provide informed consent and unavailability of a legally authorized representative to provide surrogate consent. In the case of minors, unavailability of a parent or guardian.\n2. Presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.\n3. Unavailability, or inability to adhere with the schedule for follow-up visits.\n4. Pregnancy",true,"ALL","1 Day","100 Years",{"count":22,"type":23},2000,"ESTIMATED","OBSERVATIONAL","Background:\n\nInflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD). Their causes are unknown. Researchers want to learn more about these conditions. This includes genetic changes and environmental factors.\n\nObjective:\n\nTo study sJIA and AOSD in children and adults over time.\n\nEligibility:\n\nPeople with known or suspected sJIA, AOSD, or similar inflammatory condition\n\nDesign:\n\nParticipants will be screened with a phone call.\n\nParticipants will have 1 visit. It may be outpatient or they may be admitted to the clinic. The visit may last up to 5 days. Participants will have:\n\n* Medical history\n* Physical exam\n* Musculoskeletal exam\n* Questions about overall health and quality of life, disease activity, functional status, and cognitive ability.\n\nParticipants may also have:\n\n* Pictures taken of their skin, joints, or spine\n* Blood, urine, and stool tests\n* Scans or X-rays of joints with arthritis\n* Chest X-ray\n* Heart tests\n* Skin biopsy. The skin will be numbed. The top layers of a small area will be scraped off.\n\nParticipants who have a joint aspiration may provide a fluid sample. The joint will be prepared, then fluid is removed by needle. A corticosteroid may be injected.\n\nParticipants who have a bone marrow biopsy may provide sample cells.\n\nParticipants may be seen by NIH specialists.\n\nMembers of the participant s family and healthy volunteers may give blood or saliva samples for genetic testing.\n\nParticipants may repeat some study tests every 6 months.",[27,28,29,30],"Still's Disease, Adult-Onset","Systemic Inflammation","Arthritis","Autoinflammatory Syndrome",[32,33,29,34,35],"Inflammation","Fever","Sequencing","Natural History","RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2018-05-21",{"date":44,"type":23},"2050-01-01",{"name":46,"class":47},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":4,"leadSponsor":73,"locationsCount":48},"100165130","natural-history-and-development-of-spondyloarthritis-100165130","NCT01422694","Natural History and Development of Spondyloarthritis","Studies on the Natural History and Pathogenesis of Spondyloarthritis","* INCLUSION CRITERIA\n\nTo be eligible for follow-up visits, patients must meet the Inclusion Criteria, but not the Exclusion Criteria. Subjects will provide informed consent and then be evaluated either in the outpatient or inpatient unit of the NIH Clinical Center.\n\n* Subjects with known or suspected SpA.\n* Family members of individuals with known or suspected SpA. Family members will not be asked to submit to bone marrow aspiration or interruption of therapy.\n* Controls for clinical, cellular, molecular, and biochemical assays, and genetic evaluation will be enrolled. Individuals who undergo phlebotomy specifically to provide a control specimen will be 6 years of age or older, and not pregnant.\n* Minor healthy volunteers undergoing imaging (SI and\u002For WB MRI) must be old enough to complete the procedure without sedation. Generally this requires that they be at least 6 years of age, so no healthy volunteers under age 6 will be enrolled.\n* Pregnant people with SpA are allowed to enrolled. Pregnant people will not be asked to undergo an MRI and will not be asked to submit to skin biopsy or bone marrow aspiration.\n\nEXCLUSION CRITERIA\n\n* Inability to provide informed consent or, in the case of minors, unavailability of a parent or guardian.\n* Presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.\n* Unavailability, or inability to comply with the schedule for follow-up visits.\n* Children under the age of 2 years old.\n\nThe vast majority of minors with SpA or suspected SpA will be 6 years of age or older. However, it is possible that children younger than age 6 will be evaluated. If children under age 6 are referred for evaluation, we will ensure that they do not have any acute or chronic comorbidity that would preclude them from being safely evaluated at the NIH Clinical Center. Such patients would be referred to other appropriate pediatric hospitals.\n\nBased on estimates of the incidence and prevalence of SpA in the pediatric and adult populations we set the accrual ceiling up to 2000. We hope to enroll up to 100 patients per year.","2 Years","99 Years",{"count":22,"type":23},"Background:\n\n\\- Spondyloarthritis (SpA) is a group of bone and joint disorders that may cause back and joint pain and stiffness. In some cases, SpA can lead to abnormal bone growth affecting the joints and spine. Some patients have SpA without ever developing these growths, while others develop them after only a few years. Researchers are interested in studying people with SpA and their relatives to determine which people are more likely to develop more severe conditions.\n\nObjectives:\n\n\\- To identify symptoms and medical tests that can help determine whether a person with SpA is at risk for developing more severe forms of the disease.\n\nEligibility:\n\n* Individuals of any age who have been diagnosed with SpA.\n* Healthy volunteer relatives (at least 6 years of age) of the individuals with SpA.\n\nDesign:\n\n* Participants will be screened with medical records and family medical histories, and will be invited to the clinical center for the study.\n* Participants with SpA will have a physical exam and medical history, including a study of joint movement, blood and urine tests, and questionnaires about pain and quality of life.\n* Participants with SpA will have imaging studies, including magnetic resonance imaging (MRI). Other samples such as skin tissue and bone marrow may also be collected for study.\n* Healthy volunteers will provide a blood sample and cheek cell samples.\n* No treatment will be provided, although treatment options will be discussed.",[29,61],"Spondylitis, Ankylosing",[63,64,65,66,67,35],"Sacroiliitis","Ankylosing Spondylitis","Spondyloarthritis","HLA-B27","Enthesitis-Related Arthritis","2026-06-27",{"date":70,"type":40},"2026-06-30",{"date":72,"type":40},"2011-08-12",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":20,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":4,"leadSponsor":97,"locationsCount":48},"100059944","studies-of-the-natural-history-of-rheumatic-diseases-100059944","NCT00024479","Studies of the Natural History of Rheumatic Diseases","* INCLUSION CRITERIA:\n\nKnown or suspected rheumatic disease\n\nAge greater than or equal to 18 years\n\nWillingness and capacity to provide informed consent.\n\nEXCLUSION CRITERIA:\n\nPatients will be excluded if any of the inclusion criteria cannot be met.\n\nWomen who are pregnant or breastfeeding at the time of enrollment.","18 Years",{"count":82,"type":23},7500,"This study will explore the causes of rheumatic diseases and why many of them affect certain minority communities more severely. Rheumatic diseases may cause joint pain, stiffness or swelling. Some can involve bones, muscles, tendons or ligaments. Some cause abnormalities of the immune system-the body s defense against disease. Some rheumatic diseases are painful or deforming and some can be life threatening. Information obtained from this study will be used to learn about the disparities in rheumatic disease in the minority community and to design further, more targeted, research studies to address this issue.\n\nPatients with known or suspected rheumatic disease 18 years of age or older may be eligible for this study. Candidates will undergo a medical history and physical examination to confirm the diagnosis of rheumatic disease and determine what is needed for evaluation and treatment.\n\nParticipants will receive standard medical care for rheumatic disease and arthritis. No experimental treatments, medications or procedures will be included in this study. Procedures may include routine blood tests for blood chemistries, cell counts, and antibodies commonly found in patients with rheumatic disease; a urine test for proteins and cells; and X-rays and other imaging tests to check for abnormalities in the lungs or other organs. All medical information will be kept confidential.\n\nPatients who are found to be eligible for other current NIH research studies will be offered an opportunity to participate in these studies.",[85,29],"Rheumatic Diseases",[87,88,89,35,90,91],"Minorities","Rheumatic Disease","Community Based","Ethnicity","Health Disparities","2026-06-23",{"date":94,"type":40},"2026-06-24",{"date":96,"type":40},"2001-10-03",{"name":46,"class":47},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":140},"100407038","randomized-comparison-of-partial-wrist-fusion-with-or-without-triquetral-excision-parte-100407038","NCT04580225","Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)","PARTE","Inclusion Criteria:\n\n* Participant has a stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) wrist and is a surgical candidate for the included surgical interventions\n\nExclusion Criteria:\n\n* Participant has been diagnosed with other forms of wrist arthritis other than SLAC or SNAC\n* Participant has significant arthritis of the ipsilateral hand\u002Ffinger joint(s), major joint trauma, previous major wrist surgery, infection or neuromuscular pathology affecting the function of the ipsilateral upper extremity or ability to make a fist\n* Participant has a physical or mental health condition preventing completion of consent or questionnaires\n* Participant does not speak\u002Fread\u002Funderstand English\n* Participant has no fixed address or means of contact\n* Participant is unwilling to complete necessary follow-ups\n* Surgeon concludes that eligible salvage techniques are not appropriate at the time of surgery (based on injury characteristics or concomitant wrist pathology)","75 Years",{"count":107,"type":23},170,"INTERVENTIONAL",[110],"NA","This randomized clinical trial (RCT) aims to compare clinical and radiographic outcomes of different partial wrist fusion techniques in participants with post-traumatic wrist arthritis. Participants with stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) who meet the eligibility criteria will be randomly assigned to one of two parallel groups: Group A (partial wrist arthrodesis without triquetral excision i.e. four-corner arthrodesis), or Group B (partial wrist arthrodesis with triquetral excision i.e. three-corner or capitolunate arthrodesis with triquetral excision). The results of this study will provide evidence to guide surgeons in determining the ideal wrist fusion technique in the management of patients with post-traumatic wrist arthritis requiring surgery.",[113,114,115,116,117,29,118,119],"Wrist Arthritis","Wrist Arthropathy","Scapholunate Advanced Collapse","Scaphoid Nonunion","Post-traumatic; Arthrosis","Musculoskeletal Diseases","Joint Diseases",[121,122,123,124,125,126,127,128,129,130],"Post-traumatic wrist arthritis","Partial wrist fusions","Scapholunate advanced collapse","SLAC wrist","Scaphoid nonunion advanced collapse","SNAC wrist","Four-corner fusion","Bicolumnar wrist fusion","Three-corner fusion","Capitolunate fusion","2026-06-19",{"date":94,"type":40},{"date":134,"type":40},"2021-01-07",{"date":136,"type":23},"2027-04",{"name":138,"class":139},"University of Alberta","OTHER",5,{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":17,"sex":18,"minAge":80,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":108,"phases":151,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":172},"100500488","aptis-pruj-prosthesis-for-the-treatment-of-patients-with-proximal-radial-ulna-joint-disorders-100500488","NCT05796908","Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.","A Prospective, Multi-Center, Single-Arm Clinical Trial of the Safety and Effectiveness of the Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, subjects must meet all of the following criteria:\n\n  1. Patient is skeletally mature and under 85 years of age.\n  2. Patient has a painful, unstable radial head due to degeneration or post-traumatic disabilities presenting pain, crepitation, and decreased motion at the radiohumeral and\u002For proximal radioulnar joint and is otherwise\n  3. Patients willing and able to understand and sign the informed consent. In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the post-operative rehabilitation and follow-up visits per protocol.\n\nExclusion Criteria:\n\n* 1\\. Inadequate bone stock or soft tissue coverage 2. Patients with severe humeral\u002Fulnar arthritis, defined as:\n\n  1. Pain at terminal flexion\u002Fextension\n  2. Pain throughout ROM with loss of motion in terminal flexion and\u002For extension 3. Patients with an allergy to the implant materials 4. Active systemic infection or infection at the site of surgery 5. Physical interference with or by other prostheses during implantation or use 6. Have a Body Mass Index (BMI) greater than 35 kg\u002Fm2 7. Have any mental or psychological disorder that would impair the ability to complete the study questionnaires 8. Have significant comorbidities or conditions associated with high-risk for surgical or anesthetic survival (e.g., renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.) 9. Have any medical condition or other circumstances that might interfere with the ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative rehabilitation 10. Have any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the device's safety and performance 11. Skin, bone, circulatory and\u002For neurological deficiency at or affecting the implantation site 12. Prisoners 13. Patients on chronic corticosteroid or non-steroidal anti-inflammatory therapy 14. Women who are pregnant or breast-feeding or are planning to become pregnant during the study.\n\n     15\\. Patients with a documented history of uncontrolled diabetes. 16. Patients with known allergies against anesthesia. 17. Patients with a history of or current drug and\u002For alcohol abuse 18. Patients unlikely to cooperate or are legally incompetent. 19. Patients with legal involvement, including an active claim for workman's compensation, or any other issue that would hinder completion of the two-year follow period.\n\n     20\\. Patients who are participating or have participated in any other study involving an investigational drug or device within the past 3 months.\n\n     Intra-operative Exclusion Criteria\n\n     Subjects who meet any of the following intra-operative screening criteria will be excluded from participation in this study:\n     * A proximal radio ulnar joint that cannot be reduced intraoperatively\n     * Inadequate bone quality that would allow for implant placement\n     * Not enough radius bone proximally for device implantation","85 Years",{"count":150,"type":23},84,[110],"A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders",[29,154,155,156],"Unstable Radial Head","Proximal Radioulnar Joint Instability","Decreased Motion at the Proximal Radioulnar Joint and\u002For the Radio-humeral Joint",[158,159,160,161],"PRUJ","Disorders","radio-humeral joint","proximal radioulnar joint","2026-06-10",{"date":164,"type":40},"2026-06-12",{"date":166,"type":40},"2024-04-12",{"date":168,"type":23},"2030-11",{"name":170,"class":171},"Aptis Medical","INDUSTRY",7,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":108,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":48},"100586410","impact-of-biophoton-therapy-on-chronic-severe-arthritis-pain-100586410","NCT06915012","Impact of Biophoton Therapy on Chronic Severe Arthritis Pain","A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Chronic Severe Arthritis Pain","Severe Pain","Inclusion Criteria:\n\n* Willing and able to give informed consent for participation in the trial.\n* Is able and willing to comply with all trial requirements.\n* Male or female aged 18-80 years old with chronic severe arthritis pain.\n* ≥3 months duration of chronic severe arthritis pain.\n* a current VAS pain rating ≥5\u002F10.\n* Able to complete the treatment for the study period.\n* Must be fluent in English.\n\nExclusion Criteria:\n\n* Untreated psychiatric disturbances that would affect trial participation as judged by the Caregiver or by the clinical study medical professional\n* Who relies on ventilators\n* Who had deep brain stimulators, or pacemakers, or implantable electronic devices\n* Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis.\n* Is participating in another investigational drug or device trial\n* Has an active infectious disease, such as COVID-19\n* Pregnant women.","80 Years",{"count":183,"type":23},102,[110],"Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can alleviate chronic severe pain.\n\nStudy Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in managing chronic severe pain. Approximately 102 patients with chronic severe arthritis pain will participate in the study.\n\nStudy Randomization The biostatistician will prepare a randomization schedule including a series of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group.\n\nOther than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants (and caregivers), will be blinded about who received which product during the first two weeks of study participation.\n\nStudy Enrollment Each potentially qualified patient will review the Informed Consent Form online (e-ICF) and Enrollment Criteria online (e-Criteria) first, then discuss the e-ICF and e-Criteria with the study team medical professional via telephone during the scheduled time. Each qualified patient will sign the e-ICF and send it to the Study Coordinator. The Study Coordinator will assign the qualified patient a randomized subject number, then the patient will become a study participant.\n\nStudy Procedure We expect that the participant will stay in this clinical treatment for 12 weeks, or 12 weeks if the participants are randomly placed in a placebo group. The 12 weeks of participation are double-blinded to record the placebo effects, as each set of the study device is labelled with a unique code for use by only one participant. The change of the placebo device to the treatment device will be performed by the study device management team staff, who will not inform the study participant or study research staff who are involved in study data collection. Each participant assigned to the Control Group will be treated with the 4 placebo devices on the bed. Each participant assigned to the Treatment Group will receive 4 Biophoton generator devices and placed on the bed on each side of the body. Each participant will use the Treatment or Control device for at least 8 hours every night for the 12 weeks during sleep. During the day, participants are welcome to bring the study devices and place them near the bodies during the daytime. At the end of the initial 12 weeks, study participants randomized to the Placebo group will be advised whether they will use the Open-Labeled product to treat them for 4 to 12 weeks. Only the visual analog scale of the pain data will be collected after the switch. Each participant will be guided by study team staff to perform the following tests on their assigned testing days: a visual analog scale, brief pain inventory, pain disability index, the standard SF-36 questionnaires (SF-36) for measuring life quality, the Pittsburgh Sleep Quality Index, a Patient Global Impression of Change, a Hospital Anxiety and Depression Scale, and inflammatory markers that provide objective evidence of inflammation.\n\nInvestigational Product and Mode of Administration Tesla BioHealing Biophotonizer is an over-the-counter (OTC) medical device, and it can be used by anyone who wants to increase blood circulation and reduce bodily pains. For this study, the active or inactive Biophotonizer will be labeled with a code. The participant and\u002For caregiver cannot know if the devices are active or inactive. When the participant places the devices close to the body, she\u002Fhe may or may not receive life force energy. The participant will record changes in quality of life and complete the standard study questionnaires at baseline and the end of each 2-week interval.\n\nComparator and Mode of Administration Clinical measurements will be conducted by medical professionals. The same shape, size, and weight of the device without generating biophotons is to be labeled with a random code and used as a comparator. The comparator device will be placed close to the body during sleep during the entire study period. The participant will record the life quality changes and answer the standard study questionnaires. Clinical measurements will be conducted by medical professionals.\n\nStudy Duration Estimated date of the first patient enrolled: November 15, 2024. The estimated date of the last patient completed: November 15, 2025.\n\nParticipants in the Treatment Group and Control Group will actively participate in the study for 12 or 24 weeks. Each Participant will answer the standard study questionnaires several times, respectively, at the baseline, at the end of each 2-week interval after starting the study treatment.",[29],"2026-05-20",{"date":189,"type":40},"2026-05-22",{"date":191,"type":40},"2025-03-28",{"date":193,"type":23},"2026-12-31",{"name":195,"class":139},"First Institute of All Medicines",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":108,"phases":204,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100640036","phase-3-tru-vu-wrist-positioning-aid-multi-center-implementation-within-nlhs-100640036","NCT07580976","Tru-Vu Wrist Positioning Aid Multi-Center Implementation Within NLHS","Inclusion Criteria:\n\n* Must be 18 years of age or older\n* Must be proficient in English (reading\u002Fwriting)\n* Must have been referred for wrist imaging at one of the following healthcare centers: Health Sciences Center (St. John's, NL), Bonne Bay Health Center (Norris Point, NL), or Labrador Health Center (Happy Valley-Goose Bay, NL).\n\nExclusion Criteria:\n\n* Incapable of providing informed consent",{"count":203,"type":23},1800,[205],"PHASE3","This study has two primary aims: 1) to determine whether a novel wrist x-ray positioning aid can be implemented within 3 different healthcare centers in Newfoundland and Labrador, and 2) to determine the ability of the tool to improve patient positioning in wrist x-rays. It will also learn about the number of repeat x-rays required with or without the use of the tool and radiographer confidence. The main questions it aims to answer are:\n\n1. Will the implementation of the Tru-Vu differ between an urban health center, rural clinic, and remote regional hospital?\n2. Can the Tru-Vu improve the positioning procedure for radiographers performing wrist x-rays, resulting with more useful x-rays.\n\nResearchers will compare x-rays before and after the implementation of the tool as well as between centers.\n\nTechnologist participants will:\n\n* Use the tool during the positioning procedure for wrist x-rays.\n* Provide feedback regarding tool use and perceived implementation barriers and facilitators.",[208,29],"Trauma (Including Fractures)","NOT_YET_RECRUITING","2026-05-13",{"date":212,"type":40},"2026-05-18",{"date":214,"type":23},"2026-06-14",{"date":216,"type":23},"2027-09-01",{"name":218,"class":139},"Western University",3,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":18,"minAge":227,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":48},"100096133","synovial-fluid-bank-from-arthritic-patients-100096133","NCT00512343","Synovial Fluid Bank From Arthritic Patients","Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.","Inclusion Criteria:\n\n* Significant joint effusion\n\nExclusion Criteria:\n\n* Hemorrhagic effusion\n* Traumatic effusion\n* Less than 3 ml total of collected fluid (used for routine analysis and culture)\n* Inability or refusal to consent","3 Years","95 Years",{"count":230,"type":23},500,"The objectives of this group project is to collect synovial fluid (SF) and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic\u002Fprognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.",[29],[234,29,235],"Synovial Fluid","Paired serum\u002Fsynovial fluid samples",{"date":237,"type":40},"2026-05-15",{"date":239,"type":40},"2002-06",{"date":241,"type":23},"2030-09",{"name":243,"class":139},"Gilles Boire",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":48},"100565819","a-qualitative-assessment-of-the-severity-and-impact-of-rheumatic-immune-related-adverse-events-following-immune-checkpoint-inhibitor-immunotherapy-100565819","NCT06647134","A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy","Inclusion Criteria\n\nThe criteria are:\n\n* Patients aged 18 years and above\n* English (conversational level) speaking, with the ability to give informed consent\n* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy\n\nExclusion Criteria\n\n* Acutely life-threatening or worsening cancer\n* Hearing impairment functionally limiting participation in verbal interview",{"count":251,"type":23},20,"To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.",[29,254,255],"Polymyalgia Rheumatica","Immune Checkpoint Inhibitors",[257,258,259],"arthritis","polymyalgia rheumatica","immune related adverse events","2026-04-10",{"date":262,"type":40},"2026-04-13",{"date":264,"type":40},"2024-09-11",{"date":266,"type":23},"2028-03-31",{"name":268,"class":139},"M.D. Anderson Cancer Center",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":48},"100571308","pain-in-inflammatory-joint-diseases-100571308","NCT06718569","Pain in Inflammatory Joint Diseases","Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management","Nor-Pain","Inclusion Criteria:\n\n* All patients who initiate or switch biological or targeted synthetic DMARDs\n\nExclusion Criteria:\n\n* None",{"count":278,"type":23},350,"Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.",[29,281,282,283,284,285],"Arthritis, Juvenile Idiopathic","Arthritis,Rheumatoid","Arthritis, Reactive","Arthritis, Psoriatic","Spondyloarthritis (SpA)","2026-04-07",{"date":262,"type":40},{"date":289,"type":40},"2025-11-11",{"date":291,"type":23},"2027-11",{"name":293,"class":139},"Diakonhjemmet Hospital",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":108,"phases":303,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":48},"100490441","expanding-exercise-programming-for-veterans-through-telehealth-100490441","NCT05666167","Expanding Exercise Programming for Veterans Through Telehealth","Expanding Exercise Programming for Veterans Through Telehealth (CDA 22-066)","Inclusion Criteria:\n\n* diagnosis of symptomatic knee or hip OA\n* Veterans at Eastern Colorado Healthcare System Primary Care Clinics with at least one VA visit within the past year\n* physically inactive (add definition)\n\nExclusion Criteria:\n\n* No telephone access\n* hip or knee surgery or acute meniscus or anterior cruciate ligament tear in the past six months\n* recent hospitalization for cardiovascular\u002Fcerebrovascular event\n* serious mental health condition or behavioral issues precluding participating in group exercise\n* terminal illness\n* motor neuron diseases\n* severely impaired hearing, vision, or speech\n* non-English speaking\n* current participation in another OA or exercise intervention or lifestyle change study\n* other self-reported or study team\u002Fprimary care physician deemed health condition that would prohibit participation in the study\n* no primary care physician visit in past 12 months\n* pregnant women\n* insufficient internet connectivity to participate in group telehealth",{"count":302,"type":23},50,[110],"The goal of this study is to evaluate the acceptability and feasibility of a group telehealth exercise program for Veterans with lower extremity osteoarthritis (OA). Methods: This is a randomized pilot trial where Veterans (n=50) receive a group telehealth exercise program (3 months), followed by an exercise maintenance phase (6 months) that includes either text messaging alone or text messaging plus group telehealth exercise booster sessions. The primary outcomes for this study are feasibility and acceptability of the intervention. Feasibility will be assessed through number and source of referrals, recruitment, and retention. Acceptability will be assessed through surveys and interviews for participants and providers addressing reasons for participation, satisfaction, perceived appropriateness, and overall experience containing Likert scales and both yes\u002Fno and open-ended questions. Exploratory outcomes, assessed at multiple time points during the course of the study, will measure changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and changes in performance measure and physical activity assessed remotely through individual telehealth sessions. Data will be collected at baseline, 3-, 6-, and 9-month follow-up.",[29],[307,308,309,310,311],"osteoarthritis","exercise maintenance","telehealth","group exercise","text messaging",{"date":313,"type":40},"2026-04-08",{"date":315,"type":40},"2023-04-01",{"date":317,"type":23},"2027-03-31",{"name":319,"class":320},"VA Office of Research and Development","FED",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":108,"phases":331,"briefSummary":332,"conditions":333,"keywords":339,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":48},"100583770","dose-response-of-exercise-for-arthritis-management-100583770","NCT06880653","Dose Response of Exercise for Arthritis Management","Examination of the Dose Response Relationship Between Physical Activity and Arthritis-Attributable Outcomes","DREAM","Inclusion Criteria:\n\n* 18 years or older\n* Have a doctor diagnosed form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia\n* Ability to read and write in English\n\nExclusion Criteria:\n\n* Have any contraindications to exercise (besides arthritis)\n* Engage in \\>45 min\u002Fweek of Actigraph assessed moderate to vigorous intensity activity\n* Are pregnant, breastfeeding, or planning to become pregnant in the next year\n* Are planning to relocate out of the Columbia, SC area in the next 12 months,\n* Do not have a device compatible with Fitbit\n* Have uncontrolled hypertension (e.g., systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg)\n* Plan to have a surgery that affects mobility in the next 12 months\n* Have a serious cognitive impairment.\n* Not willing to be randomized to any of the 3 conditions, do not believe they could adhere to the goals, or do not believe they could achieve the highest dose of activity (150 minutes\u002Fweek).",{"count":330,"type":23},285,[110],"The purpose of the study is to see examine the effects of 3 different levels of physical activity (45 minutes\u002Fweek, 90 minutes\u002Fweek, or 150 minutes\u002Fweek) on arthritis symptoms.",[29,334,335,336,337,338],"Rheumatoid Arthritis (RA)","Gout","Fibromyalgia (FM)","Osteoarthritis","Lupus Erythematosus, Systemic",[257,340,341],"exercise","physical activity","2026-04-02",{"date":344,"type":40},"2026-04-03",{"date":191,"type":40},{"date":347,"type":23},"2029-04-30",{"name":349,"class":139},"University of South Carolina",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":17,"sex":18,"minAge":357,"maxAge":148,"enrollmentInfo":358,"targetDuration":4,"studyType":108,"phases":360,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":378},"100632606","phase-2-long-duration-high-frequency-ultrasound-for-the-treatment-of-osteoarthritis-100632606","NCT07515872","Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis","Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis","Inclusion Criteria:\n\n* Have physician-diagnosed mild to moderate knee OA (OARSI atlas grades 1-2)\n* Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA\n* Are between 65-85 years of age\n* Report a frequent pain score between 4-7 (range: 0-10) during the week preceding enrollment\n* Report that knee pain negatively affects quality of life\n* Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study\n* Are deemed appropriate by their physician or by the study site physician to participate.\n* Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.\n* Not use or initiate use of opioid and\u002For non-opioid analgesic medications.\n* Be willing to discontinue any other interventional treatment modalities on the knee during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).\n\nExclusion Criteria:\n\n* Cannot successfully demonstrate the ability to put on and take off the device.\n* Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.\n* Participated in a clinical trial for an investigational drug and\u002For agent within 30 days prior to screening.\n* Is pregnant.\n* Is a prisoner.\n* Is non-ambulatory (unable to walk).\n* Has a pacemaker.\n* Has a malignancy in the treatment area.\n* Has an active infection, open sores, or wounds in the treatment area.\n* Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.\n* Has a known neuropathy (disease of the brain or spinal nerves).\n* Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).\n* Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months.\n* Are currently taking steroids.\n* Have any contraindication to radiograph.\n* Have a secondary cause of arthritis (metabolic or inflammatory).\n* Have a known contraindication, allergy, or hypersensitivity to corticosteroids or any component of Kenalog®-40 (if assigned to the injection group).","65 Years",{"count":359,"type":23},240,[361],"PHASE2","The purpose of this study is to assess the ability of long-duration high-frequency continuous-wave therapeutic ultrasound to alleviate knee Osteoarthritis pain over an 12-week period. The primary objective of this study is to evaluate the analgesic effect of ultrasound treatment in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of ultrasound treatment to improve joint function.",[29,364],"Osteo Arthritis of the Knee",[366,367,368,369],"high-frequency continuous ultrasound","sustained acoustic medicine","low-intensity continuous ultrasound","wearable long duration ultrasound","2026-03-31",{"date":286,"type":40},{"date":373,"type":23},"2026-05-01",{"date":375,"type":23},"2028-05-31",{"name":377,"class":171},"ZetrOZ, Inc.",2,{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":386,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":108,"phases":388,"briefSummary":390,"conditions":391,"keywords":393,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":48},"100629746","phase-1-radiation-to-treat-joint-damage-caused-by-cancer-immunotherapy-100629746","NCT07478679","Radiation to Treat Joint Damage Caused by Cancer Immunotherapy","Use of Low-Dose RADiotherapy in the Management of Immune Checkpoint- Inhibitor-ArThropathy as an Immune-Related Adverse Event (RADIATE)","Inclusion Criteria:\n\n* Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which they are receiving single agent or combination immunotherapy or within the last 6 months.\n* Rheumatologist-established diagnosis of new onset CTCAE grade 2-3 immunotherapy-induced inflammatory arthritis or activated osteoarthritis, involving one or more joints (up to 3) including but not limited to hands, shoulders, elbows, hips, knees and ankles.\n* Age ≥ 40 years.\n* ECOG performance status ≤2 (Karnofsky ≥60%).\n* Patients with ability and willingness to sign consent.\n\nExclusion Criteria:\n\n* Contraindications to radiation treatment, such as pregnancy, breast-feeding women and active collagen-vascular disease.\n* Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \\>1 year prior to consent and\u002For clear documentation states that the patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment.\n* Have not received systemic steroids within the last 3 months for the treatment of immune related adverse events.\n* History of prior autoimmune conditions, or concurrent immune related adverse events requiring systemic immunosuppressants.\n* Estimated life expectancy less than 3 months as assessed by investigators.\n* Any condition at the discretion of investigator that will preclude participation in the study.\n* History of secondary malignancy as assessed by investigators.\n* History of radiation to affected joints as assessed by investigators.","40 Years",{"count":251,"type":23},[389],"PHASE1","This study will prospectively investigate the feasibility and safety of administering LDRT in patients with immunotherapy-induced inflammatory arthritis.",[29,392],"Arthropathy",[394,392,395,396],"Radiotherapy","Immunotherapy","Cancet","2026-03-18",{"date":399,"type":40},"2026-03-23",{"date":401,"type":23},"2026-08-26",{"date":403,"type":23},"2028-09-17",{"name":405,"class":139},"University of Chicago",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":108,"phases":415,"briefSummary":416,"conditions":417,"keywords":423,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":452},"100489857","phase-2-study-of-dapansutrile-tablets-in-subjects-with-an-acute-gout-flare-100489857","NCT05658575","Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","A Multi-Center Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","Inclusion Criteria:\n\n* Male and female subjects age 18 or older\n* Clinical diagnosis of gout according to the 2015 ACR\u002FEULAR Gout Classification Criteria:\n\nA) Diagnosis of gout must be confirmed in the target joint as indicated by either the presence of monosodium urate (MSU) crystals by microscopic evaluation of synovial fluid from the target joint or bursa OR by imaging evidence of urate deposition in the target joint or bursa at the Screening\u002FBaseline Visit\u002FStudy Day 1, or\n\nB) Documented history in the target joint or bursa ; or documented history of 2 or more gout flares in the previous 18 months\n\n* Confirmation of a gout flare in the target joint that began within 96 hours prior to the Screening\u002FBaseline Visit\n* Provide written informed consent and understand and comply with all trial requirements\n\nExclusion Criteria:\n\n* Presence of any palpable and visible tophi by physical examination\n* Has ≥ 4 joints with an acute gout flare at Screening\u002FBaseline\n* Presence of active rheumatoid arthritis or other acute inflammatory arthritis\n* Evidence\u002Fsuspicion of infectious\u002Fseptic arthritis\n* Clinically significant general pain or non-gout-related joint pain that would interfere with the subject's ability to accurately assess pain in the target joint\n* Known diagnosis of chronic kidney disease or known history of renal impairment\n* Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection, if tested, within 4 weeks of the Screening\u002FBaseline\n* Active malignancy or recent malignancy with any systemic anti-cancer treatment\n* Has a hypersensitivity or allergy to OLT1177® or other drugs in its class\n* Hypersensitivity or allergy to paracetamol\u002Facetaminophen\n* Use of any prohibited concomitant medications\u002Ftherapies over the periods defined in the protocol or planned use of any prohibited concomitant medications\u002Ftherapies during the Treatment Period (including the use of paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or other pain medications within 12 hours prior to the Screening\u002F Baseline Visit\n* Use of any product containing paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or planned use during the Treatment Period (with the exception of study-provided Rescue Medication \\[paracetamol\u002Facetaminophen\\], which is permitted after completion of the first target joint pain assessment on Study Day 4",{"count":414,"type":23},300,[361,205],"The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.",[418,419,420,421,335,29,422],"Acute Gout Flare","Gout Attack","Gout Flare","Gouty Arthritis","Joint Pain",[424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442],"gout","gouty arthritis","mono-articular arthritis","NLRP3","NLRP3 inhibitor","dapansutrile","OLT1177","joint pain","inflammation","gouty Inflammation","inflammasomes","IL-1 beta","IL-1 inflammation","autoinflammatory conditions","hyperuricemia","uric acid crystal","flare","small-molecule","therapeutic","2026-03-09",{"date":445,"type":40},"2026-03-11",{"date":447,"type":40},"2023-01-06",{"date":449,"type":23},"2027-01-31",{"name":451,"class":171},"Olatec Therapeutics LLC",40,{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":108,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":4},"100620919","the-efficacy-of-ultrasonication-in-combination-with-corticosteroid-intraarticular-injection-for-arthritis-100620919","NCT07363876","The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with arthritis in the limbs.\n* Inadequate response to or contraindication for oral anti-inflammatory medications.\n* Assessed by a physician as requiring intra-articular corticosteroid injection.\n\nExclusion Criteria:\n\n* History of joint replacement (prosthetic joint) in the affected area.\n* Hip joint involvement.\n* Diagnosis of gout.\n* Infectious arthritis.\n* Presence of cellulitis at the treatment site.",{"count":460,"type":23},100,[110],"This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.\n\nUltrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.",[29,464,465,466],"Ultrasonication","Intra-articular Injections","Rheumatology","2026-01-15",{"date":469,"type":40},"2026-01-23",{"date":471,"type":23},"2025-12-29",{"date":193,"type":23},{"name":474,"class":139},"Taichung Veterans General Hospital",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":17,"sex":18,"minAge":80,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":108,"phases":485,"briefSummary":486,"conditions":487,"keywords":492,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":378},"100614820","phase-2-ultralow-dose-pet-imaging-for-18f-naf-uptake-100614820","NCT07284563","Ultralow Dose PET Imaging for 18F-NaF Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting 18F-NaF Uptake","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions\n* Concurrent treatments that may interfere with radiotracer uptake as determined by the Principle Investigator.\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.","120 Years",{"count":484,"type":23},200,[361],"The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.",[488,489,490,491,29],"Healthy Volunteer","Bone Alteration","Bone and Joint Cancer","Bone and Joint Infection",[493,494,495,496,497,498],"PET","PET\u002FCT","low dose","nuclear imaging","sodium fluoride","bone","2025-12-08",{"date":501,"type":40},"2025-12-16",{"date":503,"type":40},"2025-09-01",{"date":505,"type":23},"2030-06-30",{"name":507,"class":139},"Akiva Mintz",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100613919","comparison-between-jak-inhibitors-and-traditional-treatment-of-rheumatoid-arthritis-100613919","NCT07272850","Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis","Comparison Between Haematological Parameters and Musculoskeletal Ultrasound Findings of Rheumatoid Arthritis Patients Recieving JAK Inhibitors Versus Traditional Treatment","Inclusion Criteria:\n\n* • RA patients based on the 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classifcation criteria for RA.\n\n  * Age; 18-60\n\nExclusion Criteria:\n\n* • the presence of other autoimmune diseases (e.g., systemic lupus erythematosus or psoriatic arthritis),\n\n  * history of active infections, malignancy, or chronic diseases affecting hematological\n  * parameters (e.g., anemia unrelated to RA, chronic kidney disease)\n  * RA patients in remission\n  * pregnant and lactating female patients","60 Years",{"count":517,"type":23},72,"Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1% of the world's population \\[1\\]. The disease is characterized by synovial membrane inflammation. The impact of RA on quality of life is significant, as it can lead to considerable disability, reduced mobility, and an increased risk of additional health complications \\[2\\].\n\nCsDMARDs are the first-line drugs for RA treatment, of which methotrexate (MTX) is the cornerstone drug and monotherapy is recommended as the first choice (3).\n\nHowever, previous studies had shown that 50% of RA patients had poor treatment effect on methotrexate or inadequate response to re-medication after relapse, resulting in drug resistance (4), resulting in no significant relief of symptoms and still high disease activity. EULAR had indicated that interleukin-6 (IL-6) receptor inhibitors and JAK inhibitors may have advantages over other biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients who were not suitable for csDMARDs (5) Therefore, JAK inhibitors is used as monotherapy or combination therapy, which would provide a new strategy for clinical treatment. A few researches evaluated the relationship between PLT, RBC, Hb, red blood cells-platelet ratio (RPR), and the hemoglobin-platelet ratio (HPR) and RA disease activity. There is growing evidence that metrics like RDW and MPV, as well as the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and others have been considered to be accurate, reliable inflammatory biomarkers in autoimmune illnesses\\[6,7\\] US has proven itself to be a useful imaging method for assessing articular and periarticular inflammation in small and large joints throughout the last years High resolution musculoskeletal ultrasound (MSUS), incorporating power Doppler ultrasound (PDUS), has demonstrated to be significantly more accurate than clinical evaluation in visualizing the inflammatory process. Furthermore, relatively few studies have examined ankle joint involvement in individuals with RA who lack symptoms \\[8\\].",[520,29],"Rheumatoid Arthritis","2025-11-26",{"date":523,"type":40},"2025-12-09",{"date":525,"type":23},"2025-12-20",{"date":527,"type":23},"2026-10-20",{"name":529,"class":139},"Assiut University",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":17,"sex":18,"minAge":536,"maxAge":181,"enrollmentInfo":537,"targetDuration":538,"studyType":24,"phases":4,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":48},"100444482","the-benefits-of-natural-medicine-vitamin-iv-therapy-and-supplements-maintaining-good-health-through-nature-100444482","NCT05067998","The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature","Inclusion Criteria:\n\n* N\u002FA\n\nExclusion Criteria:\n\n* N\u002FA","21 Years",{"count":7,"type":23},"1 Week","Herbal Medicine is known as the medicinal use of herbal substances as a means of treating different conditions in the human body to ensure that the body remains in optimal health and wellness. These substances are known to contain very active ingredients in it and as such is also a very potent means of managing diseases and ailments in the body.\n\nHerbal medicine has always been a standby source of getting relief from various conditions over centuries, however, it can be categorically said that the mode of usage of these herbal substances has changed over time. Traditional healers help individuals to make meaning out of the natural herbs seen around that can be useful to one's health.\n\nHerbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Herbs can interact with other pharmaceutical medications and should be taken with care. Always seek a regular medical doctor (GP) about any health concerns and tell them about any herbal medicines you are taking or thinking of taking. Never stop taking prescribed medications in favor of herbs without first discussing it with your GP.",[541,542,29,543,544],"Anxiety Disorders and Symptoms","Fibromyalgia","Chronic Pain","Hypertension,Essential","2025-09-17",{"date":547,"type":40},"2025-09-23",{"date":549,"type":23},"2025-12-21",{"date":551,"type":23},"2026-09-17",{"name":553,"class":139},"Faith A. Richardson",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":17,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":562,"conditions":563,"keywords":584,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":48},"100497203","assessing-symptom-and-mood-dynamics-in-pain-using-the-smartphone-application-soma-100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",{"count":561,"type":23},800,"This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[543,564,565,566,567,542,568,569,570,571,572,573,29,574,575,576,577,578,579,580,581,582,583],"Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Endometriosis-related Pain","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[585,586,587,588,589,590,591,592,593],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":596,"type":40},"2025-09-19",{"date":598,"type":40},"2023-06-20",{"date":600,"type":23},"2026-05-30",{"name":602,"class":139},"Brown University",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":357,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":108,"phases":613,"briefSummary":614,"conditions":615,"keywords":626,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":4},"100604585","development-and-validation-of-a-comprehensive-management-service-package-for-older-adults-with-multimorbidity-100604585","NCT07151430","Development and Validation of a Comprehensive Management Service Package for Older Adults With Multimorbidity","Development and Validation of a Comprehensive Management Service Package for Older Adults With Multimorbidity: A Randomized Controlled Trial","COMPASS","Inclusion Criteria:\n\n1. Age ≥65 years\n2. Diagnosed with ≥2 chronic diseases or geriatric syndromes (e.g., hypertension, diabetes, frailty, depression)\n3. Willing to provide informed consent\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C1 year due to severe illness (e.g., cardiogenic shock)\n2. Currently participating in other clinical trials",{"count":612,"type":23},358,[110],"This study aims to test a new comprehensive management service package for older adults with two or more chronic conditions (multimorbidity). The package includes digital health tools, personalized guidance, and long-term management support. Researchers will compare the service package with usual care to see whether it reduces hospital readmissions, improves quality of life, and supports daily functioning. About 394 participants will be randomly assigned to either the service package group or the usual care group. Participants will be followed for 6 months to measure health outcomes, treatment adherence, and safety.",[616,617,618,619,620,621,29,622,623,624,625],"Multimorbidity","Hypertension","Diabetes Mellitus","Coronary Artery Disease","Dyslipidemia","Stroke","Cognitive Impairment","Depression - Major Depressive Disorder","Chronic Kidney Disease","Chronic Liver Diseases",[627,628,629,630],"management service package","multimorbidity","quality of life","intrinsic capacity","2025-08-28",{"date":633,"type":40},"2025-09-03",{"date":635,"type":23},"2025-12-01",{"date":637,"type":23},"2026-12-01",{"name":639,"class":139},"Xuanwu Hospital, Beijing",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":646,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":650,"conditions":651,"keywords":652,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":48},"100601164","early-stratification-of-acute-arthritis-100601164","NCT07106931","Early STratification of Acute ARThritis","Early STratification of Acute ARThritis (START)- A Prospective Observational Study","START","Inclusion Criteria:\n\n* Arthritis\\* in one or more joints of less than 12 weeks' duration\\*\\*\n* Adult patients (\\> 18 years) capable of understanding and signing an informed consent form\n\n  * Defined as currently active clinical synovitis (ie, swelling) in at least one joint as determined by an expert assessor which might be confirmed by ultrasonography \\*\\* Prior patient reported swollen joint not confirmed as arthritis by a rheumatologist is not an exclusion\n\nExclusion Criteria:\n\n* Swollen joint related to trauma\n* Subject not capable of adhering to the study protocol",{"count":649,"type":23},400,"The prospective observational study \"Early STratification of acute inflammatory ARThritis\" (START) aims to build a platform for identification of markers for early stratification of inflammatory arthritis to ensure timely diagnosis and correct initial treatment. Management of early-stage inflammatory arthritis is a daily challenge for the rheumatologist and encompasses a range of conditions. Stratification is needed both for optimal diagnostics and for personalising therapy, but is hampered by a lack of tools. Current evaluation is inadequate for early diagnosis and treatment of inflammatory joint diseases as well as for timely diagnosis of infections. The clinical role of novel biomarkers needs to be investigated in large patient samples. In the START study, an extensive data collection will be performed to build a platform for identification and validation of biomarkers for stratification of early-stage inflammatory arthritis. The study has an ambitious goal of improving patient care by increased understanding of the disease. The project applies a unique multitude of approaches to characterisation of patients, including modern imaging techniques, analyses of synovial fluid and -biopsies, genetic and epigenetic markers, proteomics, microbiota analyses and immunological markers. The results will enable clinicians to make better informed treatment decisions for the individual patient with early-stage inflammatory arthritis.",[29],[653],"early onset arthritis","2025-08-04",{"date":656,"type":40},"2025-08-06",{"date":658,"type":40},"2024-11-05",{"date":660,"type":23},"2044-12-31",{"name":293,"class":139},{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":108,"phases":672,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":48},"100389728","phase-2-immune-mediated-pathophysiology-and-clinical-triage-program-100389728","NCT04354649","Immune-Mediated Pathophysiology And Clinical Triage Program","A Study to Evaluate the Efficacy and Safety Hydroxychloroquine in Immune Related Arthritis or Arthralgias","IMPACT 2","Inclusion Criteria:\n\n1. Patients must be 18 years of age, or older;\n2. Patients must be capable of providing consent to enrolment and treatment.\n3. Patients with a performance status of ECOG 0-2 will be eligible for enrolment (see appendix A).\n4. Patients with histologically confirmed cancer receiving anti-PD1 or anti-PDL1 monoclonal antibody ICI therapy, either alone or in combination with anti-CTLA4 monoclonal antibody ICI therapy who develop CTCAEv5.0 grade ≥2 arthritis or arthralgia that has developed on, or after, ICI therapy and is felt to be treatment related (irAA).\n5. Adequate hepatic and renal function defined by the following laboratory parameters:\n\n   * AST and ALT and alkaline phosphatase ≤ 2.5x ULN,\n   * Total bilirubin ≤ 1.5x ULN,\n   * Serum creatinine ≤ upper limit of institutional normal OR calculated creatinine clearance of ≥ 60 mL\u002Fmin using the Cockcroft-Gault formula.\n6. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level \\> 40 mIU\u002FmL to confirm menopause.\n7. Patients of childbearing \u002F reproductive potential should use highly effective birth control methods, during the study treatment period and for a period of 3 months after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. These may include: hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation. Double-barrier methods may be acceptable in circumstances when highly effective methods cannot be implemented (e.g. male condom with diaphragm, male condom with cervical cap). Note: Contraceptive requirements for the oncology regiments will apply, if they are more stringent than those for this trial. Abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.\n8. Female patients who are breast-feeding should discontinue nursing prior to the first dose of study treatment and until 3 months after the last dose of study drug.\n9. Male patients should agree to not donate sperm during the study and for a period of at least 3 months after last dose of study drug.\n10. Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial.\n\nExclusion Criteria:\n\n1. History of inflammatory arthritis, including, but not limited to: Rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, Ankylosing spondylitis or other chronic inflammatory arthritis. Note: Patients with a known history of stable osteoarthritis will not be excluded.\n2. Patients with an indication for systemic immunosuppressive medications or corticosteroids. Patients with CTCAEv5.0 grade ≥2 irAE's other than irIAA (ie. colitis, pneumonitis, rash, etc) are not eligible for trial, with the exception of endocrinopathies that are being treated with hormone replacement alone and not systemic immunosuppressive medications or corticosteroids.\n3. Patients weighing \\\u003C 40 kg.\n4. Patients with G6PD deficiency, porphyria or psoriasis.\n5. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident\u002Fstroke (\\\u003C 6 months prior to enrollment), myocardial infarction (\\\u003C 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.\n6. Prolonged corrected QT interval or concurrent medications that prolong QT interval.\n7. Diagnosis of immunodeficiency.\n8. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n9. Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (CTCAEv5.0 Grade ≥ 3).\n10. Other severe acute or chronic medical conditions including inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.",{"count":671,"type":23},46,[361],"Many people develop joint pain, stiffness and swelling due to their cancer treatment that targets the immune system. The severity of symptoms ranges from mild to debilitating and sometimes requires delaying or stopping cancer treatment.\n\nThe usual plan is to discontinue cancer treatment and give relatively high doses of a medication called prednisone (a steroid, which is an anti-inflammatory medication which may suppress the immune system) with a gradual lowering of the dose over several weeks. While this can be effective, prednisone can cause a number of side effects, and it is not known if this is the best or safest treatment.\n\nHydroxychloroquine is a medication that is often used to treat inflammatory joint pain, such as rheumatoid arthritis, has relatively few side effects when compared to prednisone, and may be effective at treating this condition.\n\nThe purpose of this study is to find out whether it is better to receive hydroxychloroquine and prednisone, or prednisone alone for joint pain. To do this, some participants will get hydroxychloroquine and some will receive a placebo (a substance that looks like the study drug but does not have any active or medicinal ingredients). A placebo is used to make the results of the study more reliable.\n\nThis is a double-blinded study, which means that neither participants nor the study doctor or study staff will know which group participants are allocated. After 12 weeks of study treatment, the blind will be opened and participants will be informed which treatment was given.",[29,675],"Arthralgia","2025-06-16",{"date":678,"type":40},"2025-06-18",{"date":680,"type":40},"2021-09-16",{"date":682,"type":23},"2029-07",{"name":684,"class":139},"AHS Cancer Control Alberta",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":690,"acronym":691,"eligibilityCriteria":692,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":693,"enrollmentInfo":694,"targetDuration":4,"studyType":108,"phases":696,"briefSummary":697,"conditions":698,"keywords":702,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":708,"lastUpdatePostDateStruct":709,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":48},"100338454","phase-1-evaluation-of-superiority-of-valsartancelecoxibmetformin-over-metformin-alone-in-type-2-diabetes-patients-100338454","NCT03686657","Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients","RESILIENCE","Inclusion Criteria:\n\n1. Males and females, Age: \\>18 to 70 years at the time of screening visit.\n2. Women of childbearing potential (WOCBP) must have negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent of HCG) within 24 hours prior to the start of the study.\n3. Women must not be breastfeeding.\n4. HbA1c≥8.0\n5. Patients with inadequate blood glucose control with Metformin defined as a central laboratory glycosylated hemoglobin (HbA1c) \\>8.0 and \\\u003C10.5 obtained at the screening visit. Metformin-HCl monotherapy was inadequate 3 months prior to the study as indicated by the lack of decrease and\u002For an increase in the A1c level.\n\n   Newly diagnosed drug naïve patients as defined by HbA1c\\>7.0 at the screening visit. Drug naïve subjects diagnosed with type 2 diabetes within 6 months of diagnosis will be considered and selected.\n\n   About half the patients are expected to be newly diagnosed in the study.\n6. Drug naive as well as osteoarthritis patients with Type 2 diabetes receiving a non-aspirin pain reliever (e.g. acetaminophen) or an NSAID (e.g. Naproxen).\n7. Max\u002Fmaintenance dose Metformin. Subjects should have been taking the same daily dose of metformin for at least 8 weeks prior to the enrollment visit and subjects not receive these other antihyperglycemic medications within the 12 weeks prior to screening (except for short-term use of insulin \\[≤7 days\\] during concomitant illness or other stress).\n8. Patients with \\>25% AIRg at 2 minutes and 10 minutes.\n9. RAS blocker naïve patients\n10. 2-Hour OGTT ≥200 mg\u002FdL\n11. FPG ≥140 mg\u002FdL\n12. BMI ≥30\n13. Impaired first phase and second phase of insulin secretion\n14. BP ≥140\u002F90 mm Hg (These patients might be on an anti-hypertensive drug)\n15. Non-fasting laboratory glucose \\>200 mg\u002FdL with symptoms of polydipsia, polyuria and\u002For Polyphagia\n16. eGFR ≥ 60 ml\u002Fmin\u002F1.73m2\n\nExclusion Criteria:\n\n1. Age \\>70\n2. Patients with Type 1 diabetes, Screen for GAD (Glutamic acid decarboxylase) antibodies at the time of screening visit. To rule out latent autoimmune diabetes in adults (LADA), screening for other diabetes-related antibodies, such as insulinoma-associated protein (IA-2 and IA-2 beta), zinc transporter-8 (ZnT8), islet cell antibodies (ICA) or insulin autoantibody (IAA) will also be considered.\n3. Pregnant women\n4. Patients with a history of Ketoacidosis.\n5. Subjects at serious risk of gastrointestinal (GI) adverse events (e.g. current or recent history of GI bleeding ulceration, or perforation).\n6. Subjects with a planned radiologic study with intravenous contrast, surgery, or other planned procedures that may predispose them to metformin-associated lactic acidosis.\n7. Insulin dependent: \\\u003C25% Beta-cell function: AIRg (Acute insulin response to glucose after 2 min and 10 min after glucose injection) INSULIN DEPENDENT STATE.\n8. Patients with a history of uncontrolled hyperglycemia \\>15.0 mmol\u002FL (280 mg\u002FdL) after an overnight fast that required rescue therapy.\n9. Patients with uncontrolled hyperglycemia \\>15.0 mmol\u002FL (280 mg\u002FdL) after an overnight fast that required rescue therapy during week 1-3 Metformin-HCl monotherapy or RK-01 therapy.\n10. eGFR, impaired kidney function \\\u003C 60 ml\u002Fmin\u002F1.73m2.\n11. Poor metabolizers of Cyp450 2C9 to avoid very high concentration (Since Cytochrome 450 2C9 is responsible for the metabolism of both Valsartan and Celecoxib, patients who are known or suspected to be poor Cyp450 2C9 metabolizers based on previous history will be excluded from the study).\n12. Any of the following cardiovascular (CV)\u002FVascular diseases within 3 months of the enrollment visit:\n\n    1. Myocardial infarction (MI)\n    2. Cardiac surgery or revascularization (coronary artery bypass surgery, Coronary Artery Bypass Graft \\[(CABG\\]\u002FPercutaneous transluminal coronary angioplasty (PTCA)\\].\n    3. Unstable angina\n    4. Unstable congestive heart failure (CHF)\n    5. Transient ischemic attack (TIA) or significant cerebrovascular disease\n    6. Unstable or previously diagnosed arrhythmia\n    7. Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute heart failure and\u002For known left ventricular ejection fraction of ≤40%.\n    8. Acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to the informed consent.\n13. Previous bariatric surgery\n14. Treatment with anti-obesity drugs within 3 months prior to consent\n15. Patients with COPD\n16. Patients with liver disease\n17. Patients with renal disease\n18. Patients with autoimmune diseases e.g. Lupus, Psoriasis\n19. Patients with HIV\u002FAIDS\n20. Patients with diabetes-related complications\n21. Patients with Hematological and Oncological Diseases\u002FConditions\n22. Hemoglobin \\\u003C11.0 g\u002FdL (110 g\u002FL) for men; hemoglobin \\\u003C10.0 g\u002FdL (100 g\u002FL) for women\n23. Patients with chronic disease e.g. Cancer, Epilepsy, Alzheimer, Parkinson, Asthma\n24. Abnormal free T4\n25. Patients with serious infection","70 Years",{"count":695,"type":23},115,[389,361],"Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise over 26 weeks of treatment.\n\nObjective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy.\n\nHypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.",[699,700,29,701],"Type 2 Diabetes","High Blood Pressure","Obesity",[703,701,704,705,706,707],"Diabetes","FPG","Beta cell function index","HbA1c","Atherogenic index","2025-05-29",{"date":710,"type":40},"2025-06-03",{"date":712,"type":23},"2025-10-10",{"date":714,"type":23},"2029-01-31",{"name":716,"class":171},"ARKAY Therapeutics",{"id":718,"slug":719,"hasResults":12,"nctId":720,"briefTitle":721,"officialTitle":722,"acronym":4,"eligibilityCriteria":723,"healthyVolunteers":12,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":724,"targetDuration":4,"studyType":108,"phases":726,"briefSummary":727,"conditions":728,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":731,"lastUpdatePostDateStruct":732,"startDateStruct":734,"completionDateStruct":736,"leadSponsor":738,"locationsCount":48},"100491446","hydrogel-coating-to-reduce-post-surgical-infection-after-joint-arthroplasty-100491446","NCT05679232","Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty","Randomized, Controlled, Monocentric, Feasibility Clinical Investigation to Assess the Safety and Preliminary Clinical Performance of a Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* Males and females aged over 18 years at time of surgery\n* Subjects who are scheduled to receive a conical collarless cementless revision hip arthroplasty, with or without revision of the acetabular cup\n* Subjects willing to comply with the pre- and post-operative evaluation schedule\n\nExclusion Criteria:\n\n* Subjects with one or more medical conditions identified as a contraindication defined by the labelling on any implants used in this study\n* Subjects with immune suppressive treatment for organ transplantation, or known allergy to MectaShield hydrogel constituents (Chitlac, Mannitol, Hydroxypropylmethylcellulose, Sodium phosphate dibasic)\n* Subjects presenting with progressive local or systemic infection at the time of surgery\n* Subjects whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems\n* Subjects affected by concomitant spine, hip, ankle or contralateral knee pathologies that can affect walking capacity\n* Subjects unable to understand and take action\n* Subjects undergoing cementless revision hip arthroplasty in emergency interventions",{"count":725,"type":23},56,[110],"The goal of this randomized, controlled, monocentric, single-blind, 2-arm, feasibility clinical investigation is to evaluate the safety of MectaShield hydrogel coating and to capture its preliminary clinical performance in the prevention of early peri-prosthetic joint infection (PJI) in patients undergoing cementless revision hip arthroplasty.\n\nThe main questions it aims to answer are:\n\n* demonstrate that the hydrogel coating MectaShield does not interfere with primary stability;\n* evaluate clinical and functional outcomes, the rate of PJI and possible adverse events.\n\nParticipants will undergo cementless revision hip arthroplasty; during surgery MectaShield hydrogel coating is applied on orthopaedic implants' surfaces (femoral stem and, if revised, acetabular cup) as a protective barrier for the prevention of bacterial adhesion. Surgery and follow-up are completed as per local standard practice. Stability will be assessed radiologically, while functional outcomes and PJI will be monitored by HOOS-PS, ASESPIS scores and according to the consensus document presented by European Society of Radiology (ESRa), the European Association of Nuclear Medicine (EANM), the European Bone and Joint Infection Society (EBJIS), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Researchers will compare the results of the treatment group with those from a control group receiving cementless revision hip arthroplasty without the application of MectaShiled hydrogel coating.",[29,729,730],"Traumatic Arthritis","Avascular Necrosis","2025-05-07",{"date":733,"type":40},"2025-05-11",{"date":735,"type":40},"2022-12-06",{"date":737,"type":23},"2027-12-06",{"name":739,"class":171},"Medacta International SA"]